FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 03:43:38 2024-05-31 pm EDT | ||
| 5.63 EUR | -1.05% |
|
| 3 months | +92.81% | ||
| 6 months | +68.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 5.63 | -1.05% |
| 24-05-30 | 5.69 | -5.17% |
| 24-05-29 | 6 | +4.17% |
| 24-05-28 | 5.76 | +17.55% |
| 24-05-27 | 4.9 | +0.62% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 03:43 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ33CG |
| ISIN | DE000SQ33CG7 |
| Date issued | 2022-11-10 |
| Strike | 82.13 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.43 € |
|---|---|
| Lowest since issue | 0.88 € |
| Spread | 0.06 € |
| Spread % | 1.08% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.27
USD
Average target price
82.7
USD
Spread / Average Target
+28.67%
- Stock Market
- Certificates
- Certificat
